Rectal Cancer Stages

Rectal cancer in India sits inside the larger colorectal disease burden of roughly 65,000 new diagnoses and 38,000 deaths a year recorded in GLOBOCAN 2022, but the rectum is treated as a distinct cancer because the tumour grows inside the narrow bony pelvis where the bladder, prostate or vagina, autonomic nerves and the mesorectal fascia all share planes that change every surgical and radiation decision. The single variable that decides whether a patient with a rectal tumour at a tertiary cancer centre Delhi, a tertiary cancer centre, a tertiary cancer centre Rohini, a leading cancer centre Gurgaon, leading cancer centres Saket, a leading cancer centre Indraprastha, a leading cancer centre Dwarka, a leading cancer centre or a leading cancer centre Noida ends up under transanal microsurgery, total neoadjuvant therapy followed by total mesorectal excision, watch-and-wait organ preservation, or first-line palliative chemotherapy with a biologic, is the AJCC TNM 8 stage at diagnosis combined with the structured pelvic MRI report. This page explains how rectal cancer is staged across NCR tertiary centres, what every stage looks like clinically, and what families can expect at each step. (See the GLOBOCAN India 2022 fact sheet and the NCI PDQ on rectal cancer treatment.)

What Rectal Cancer Staging Actually Means

Staging in rectal cancer is the formal exercise of measuring how deep the tumour has invaded the rectal wall, how many regional mesorectal and lateral pelvic lymph nodes it has reached, whether it has crossed or is threatening the mesorectal fascia, whether extramural vascular invasion is present, and whether it has seeded the liver, lung, peritoneum or any other distant site. The rectal stage is built from three anatomic descriptors: the depth of mural invasion (T), the number of involved regional nodes (N) and the presence or absence of distant metastases (M), with two pelvic-specific add-ons that only apply to rectal disease, the mesorectal fascia status and extramural vascular invasion read off the rectal MRI. leading cancer centres and the a leading cancer centre group all use the AJCC and UICC TNM 8th edition for rectal cancer, so a Stage IIIB rectal adenocarcinoma reported at a leading cancer centre Indraprastha means the same thing as a Stage IIIB reported at a leading cancer centre Dwarka. (See the AJCC Cancer Staging Manual 8th edition colon and rectum chapter and the UICC TNM resources.)

Why Rectal Cancer Uses TNM 8 With cTNM, pTNM and ypTNM Groups

The 8th edition of TNM has been the standard for rectal cancer reporting at every NCR tertiary centre since 2017 and is the first to formally separate clinical (cTNM), pathological (pTNM) and post-neoadjuvant (ypTNM) stage groupings. This separation matters more for the rectum than for any other gastrointestinal site because total neoadjuvant therapy with RAPIDO short-course radiotherapy and CAPOX or with PRODIGE 23 induction FOLFIRINOX followed by long-course chemoradiation is now the default for any cT3, cT4 or node-positive mid and low rectal tumour, which means the histology read on the resected specimen has already been reshaped by chemotherapy and radiation and is no longer comparable to the pre-treatment clinical stage. a tertiary cancer centre, a tertiary cancer centre video MDT, a tertiary cancer centre, a leading cancer centre and the a leading cancer centre Memorial GI tumour board record cTNM after staging colonoscopy and rectal MRI, then ypTNM after the TME specimen is reported, and use both stages together to decide on adjuvant CAPOX completion and surveillance intensity. (See the ESMO localised rectal cancer guideline.)

Adenocarcinoma Dominates: WHO 5 Histologic Subtypes of Rectal Cancer

Roughly 90 to 95 per cent of rectal cancers are adenocarcinomas arising from the glandular lining of the rectum through a years-long sequence of normal mucosa to adenoma to carcinoma. The 2019 WHO Classification of Tumours of the Digestive System, 5th edition, divides rectal adenocarcinoma into conventional (NOS) tubular and papillary patterns, mucinous (more than 50 per cent extracellular mucin), poorly cohesive including the signet-ring cell variant, medullary, serrated, micropapillary, adenosquamous and undifferentiated carcinomas. a tertiary cancer centre pathology, leading cancer centres histopathology, a leading cancer centre and the a leading cancer centre Memorial reference laboratory all report under this WHO 5 framework on every rectal biopsy and TME specimen, because tubular and papillary patterns behave differently from poorly cohesive signet-ring rectal tumours that present at a younger age and a more advanced stage in Indian series from the a tertiary cancer centre and a tertiary cancer centre familial cancer clinics. (See the IARC WHO Classification of Digestive System Tumours, 5th edition.)

Mucinous and Signet-Ring Rectal Cancer: Why Histology Changes the Plan

Mucinous rectal adenocarcinoma accounts for roughly ten to fifteen per cent of rectal cases at a tertiary cancer centre and a tertiary cancer centre series and tends to present at a higher T stage with a higher rate of mesorectal fascia threat on MRI, which pushes the multidisciplinary tumour board towards total neoadjuvant therapy rather than upfront surgery. Signet-ring cell rectal carcinoma is rarer at under one per cent of cases but is aggressive, often diagnosed at Stage III or IV, and is the histology most commonly linked to peritoneal carcinomatosis and Krukenberg ovarian deposits in young Indian women, a pattern flagged by the a tertiary cancer centre Rohini and a leading cancer centre GI surgical oncology audits. Both subtypes show lower pathological complete response rates after standard chemoradiation than conventional adenocarcinoma, and a tertiary cancer centre, a tertiary cancer centre and the a leading cancer centre GI MDTs typically intensify the neoadjuvant strategy with FOLFIRINOX-based induction or accept earlier interval surgery rather than commit to a watch-and-wait pathway. (See the a tertiary cancer centre Evidence Based Management of Cancers in India, gastrointestinal volume.)

MMR Status and MSI-H Rectal Cancer: The Cercek Dostarlimab Story

Mismatch repair deficiency, recorded as loss of MLH1, MSH2, MSH6 or PMS2 staining on universal immunohistochemistry at leading cancer centres in the region Memorial pathology, identifies about twelve to fifteen per cent of locally advanced rectal cancers and four to five per cent of metastatic rectal cancers. The landmark Memorial Sloan Kettering study by Cercek and colleagues gave dostarlimab single-agent immunotherapy for six months to patients with mismatch repair deficient locally advanced rectal cancer and reported a clinical complete response in every treated patient, with no surgery and no radiation needed at two years of follow up in the initial cohort, and the AZUR-1 confirmatory study is now extending this signal in larger numbers. a tertiary cancer centre, a tertiary cancer centre video MDT and selected NCR private boards offer dostarlimab or pembrolizumab to dMMR rectal patients through compassionate access or trial protocols, with universal MMR IHC at biopsy treated as mandatory before any treatment decision. (See the Cercek et al. PD-1 blockade in mismatch repair deficient locally advanced rectal cancer, NEJM.)

RAS, BRAF and HER2 in Rectal Cancer Molecular Profiling

For any patient with metastatic rectal adenocarcinoma the minimum molecular set required before starting first-line systemic therapy at leading cancer centres in the region Memorial, a leading cancer centre Saket, a leading cancer centre Indraprastha, a leading cancer centre Dwarka and a leading cancer centre is KRAS exons two, three and four plus NRAS, BRAF V600E, HER2 amplification by immunohistochemistry and FISH or NGS, and NTRK fusion testing, in line with ESMO 2023 and NCCN guidance adapted by the Indian Council of Medical Research consensus document on colorectal cancer. RAS wild-type left-sided rectal tumours show the strongest response to anti-EGFR antibodies cetuximab or panitumumab, RAS mutant tumours receive bevacizumab, BRAF V600E mutant rectal tumours carry the worst prognosis and trigger consideration of FOLFOXIRI plus bevacizumab in the first line followed by encorafenib plus cetuximab on relapse, and HER2 amplified RAS wild-type tumours qualify for trastuzumab plus tucatinib or trastuzumab deruxtecan. (See the ICMR Consensus Document for Management of Colorectal Cancer and the ESMO metastatic colorectal cancer guideline 2023 update.)

The T Descriptor in Rectal Cancer: Tis Through T4b

Tis in rectal cancer is carcinoma in situ confined to the mucosa with no breach of the muscularis mucosae and is treated as endoscopic disease. T1 invades the submucosa and is sub-staged for pedunculated and sessile rectal polyps using the Kikuchi sm1, sm2 and sm3 system, since deep submucosal invasion at sm3 carries a nodal risk of around fifteen per cent and pushes the patient from endoscopic to formal TME surgery. T2 invades the muscularis propria. T3 invades through the muscularis propria into the perirectal fat, and the depth of extramural spread in millimetres is reported separately on the rectal MRI because depths greater than 5 mm carry a worse prognosis and a higher chance of mesorectal fascia threat. T4a perforates the visceral peritoneum on the upper third of the rectum and T4b directly invades or is adherent to the bladder, prostate, vagina, sacrum or pelvic side wall. a tertiary cancer centre, a tertiary cancer centre and the Indian Radiological and Imaging Association rectal MRI template all record the T descriptor with millimetre extramural depth on every staging report. (See the Indian Radiological and Imaging Association rectal MRI structured reporting template.)

Early Rectal Cancer: T1 sm1/sm2/sm3 and TEM/TAMIS Eligibility

Early rectal cancer means a T1 lesion with favourable histology, defined at leading cancer centres in the region GI surgical pathology as well or moderately differentiated, no lymphovascular invasion, no tumour budding, sm1 invasion under 1000 microns, and a clear deep margin of at least 1 mm. These tumours can be removed by transanal endoscopic microsurgery (TEM) or transanal minimally invasive surgery (TAMIS), routinely performed at a tertiary cancer centre GI surgery, a leading cancer centre colorectal unit and a leading cancer centre robotic surgery, with three-monthly site checks for the first year and six-monthly thereafter. Unfavourable T1 polyp cancers and sessile T1 sm2 or sm3 lesions need formal TME surgery with regional lymphadenectomy because the residual nodal risk justifies the larger operation. Endoscopic ultrasound is used at a tertiary cancer centre, a tertiary cancer centre, ILBS and a leading cancer centre whenever the rectal MRI cannot resolve early T1 versus T2 disease that may be eligible for transanal local excision instead of total mesorectal excision. (See the NCI PDQ Rectal Cancer Treatment, early stage section.)

The N Descriptor in Rectal Cancer: Why 12 Nodes and What N1c Means

The pathological N stage in rectal cancer requires a minimum of twelve regional mesorectal and pericolic nodes examined on the TME specimen, the audited yield benchmark used at a tertiary cancer centre pathology rounds and a tertiary cancer centre quality reviews. N0 means no positive nodes with at least twelve nodes assessed. N1a is one positive node, N1b is two to three, and N1c is the unique rectal category for tumour deposits in the mesorectum or perirectal tissues without identifiable nodal architecture, an N descriptor that carries the same prognostic weight as positive nodes and is reported on every a tertiary cancer centre and a tertiary cancer centre rectal histopathology sheet. N2a is four to six positive nodes and N2b is seven or more. The lateral pelvic nodal compartment in low rectal cancers is reported separately on the rectal MRI structured template, since lateral nodal involvement at the obturator or internal iliac stations may push selected patients towards lateral pelvic node dissection at high-volume Indian centres or boost radiation to the lateral compartments. (See the a tertiary cancer centre Department of Surgical Disciplines and GI surgery annual reports.)

The M Descriptor in Rectal Cancer: Liver, Lung, Peritoneum and Krukenberg Spread

The M descriptor in rectal cancer is M0 for no distant disease, M1a for metastasis confined to one organ or site without peritoneal involvement, M1b for metastasis in two or more organs without peritoneal disease, and M1c for peritoneal carcinomatosis with or without other organ involvement. The most common pattern in rectal cancer is liver-dominant disease through the portal venous drainage, followed by lung deposits seeded through the inferior rectal venous return that bypasses the portal system and explains why low rectal tumours metastasise to the lung more often than colon tumours. Peritoneal carcinomatosis with or without ascites and the rare Sister Mary Joseph umbilical nodule, ovarian Krukenberg deposits in women with signet-ring or mucinous histology, retroperitoneal nodal disease and bone metastases to the spine and pelvis are the other recognised M1 patterns reported at leading cancer centres in the region MDTs. (See the NCI PDQ Colon Cancer Treatment for the colorectal M descriptor framework.)

MRF Status and EMVI on Rectal MRI: The Hidden Sub-Stage

For rectal cancer the AJCC TNM 8 stage on its own is not enough, and the structured high-resolution pelvic MRI on a 3 Tesla magnet adds two pelvis-specific descriptors that drive the choice between upfront TME, short-course radiotherapy and total neoadjuvant therapy. The mesorectal fascia (MRF) is recorded as clear if the closest tumour edge or involved node is more than 1 mm from the fascial envelope, threatened if 1 mm or less, and involved if the tumour or a deposit reaches the fascia, since a threatened or involved MRF predicts a positive circumferential resection margin and local recurrence after surgery. Extramural vascular invasion (EMVI) is recorded as positive when tumour signal extends into the perirectal venous channels on T2 imaging and is an independent predictor of distant metastases. a tertiary cancer centre, a tertiary cancer centre, ILBS, a leading cancer centre, a leading cancer centre Memorial, a leading cancer centre and a leading cancer centre imaging report MRF, EMVI, distance from the anal verge and lateral pelvic nodal status on every staging rectal MRI per the IRIA structured template. (See the IRIA structured rectal MRI reporting template.)

Stage 0 and Stage I Rectal Cancer: Symptoms and Bleeding Patterns

Stage 0 and Stage I rectal cancer are usually picked up because of bleeding per rectum, often mistaken for haemorrhoids in primary care for many months, or on a positive screening colonoscopy in patients with a family history or known Lynch syndrome. The classic early rectal symptoms recorded in a tertiary cancer centre and a tertiary cancer centre Rohini outpatient audits include bright red blood streaking the stool, mucus discharge, the constant feeling of incomplete evacuation called tenesmus, and pencil-thin or ribbon stools as the lumen begins to narrow. Many young Indian patients in their thirties and forties present to primary care with months of rectal bleeding that is treated as piles before a colorectal surgeon finally requests a colonoscopy and rectal MRI, a delay flagged by a tertiary cancer centre and a tertiary cancer centre colorectal series and one of the strongest reasons HealOnco insists that any new rectal bleeding lasting more than four weeks deserves a flexible sigmoidoscopy regardless of age. (See the ICMR National Cancer Registry Programme Hospital Based Cancer Registries 2020 report.)

Stage II and Stage III Rectal Cancer Red Flags: Tenesmus, Pencil Stools and Sacral Pain

Stage II rectal cancer adds deeper mural invasion through the muscularis propria and into the perirectal fat or onto adjacent pelvic structures, and Stage III adds nodal involvement, but the symptoms experienced by the patient overlap heavily with Stage I disease. Worsening tenesmus, persistent pencil-thin stools, increasing volumes of dark or mixed blood, mucus, low backache and a new dragging pain in the perineum or sacrum are the most common red flags recorded at a tertiary cancer centre GI surgery, a tertiary cancer centre Rohini colorectal clinic, a leading cancer centre and a leading cancer centre outpatient audits. New onset urinary symptoms, vaginal bleeding or pneumaturia in a patient with rectal cancer suggests T4b invasion of the bladder, prostate or vagina and is a surgical emergency for restaging with rectal MRI and pelvic CT before treatment planning. The diagnosis of Stage II versus Stage III is rarely possible from symptoms alone and comes from the combination of pelvic MRI, biopsy histology and TME pathology. (See the a tertiary cancer centre Rohini GI surgical oncology audit reports.)

Stage IV Rectal Cancer Presentations: Liver, Lung and Peritoneal Disease

Stage IV rectal cancer presents through the symptoms of distant spread rather than the primary tumour, and the pattern depends on which organ has been seeded. Liver-dominant disease causes right upper quadrant heaviness, raised liver enzymes on a routine panel, jaundice if hilar nodes are involved, and weight loss. Lung-dominant disease, which is more common in low rectal cancer because of the inferior rectal venous drainage, causes a persistent dry cough, breathlessness on exertion and occasionally haemoptysis. Peritoneal carcinomatosis presents with progressive ascites, early satiety, sub-acute small bowel obstruction and the rare Sister Mary Joseph umbilical nodule. Bone metastases to the lumbar spine, sacrum or pelvis cause localised pain or hypercalcaemia. Ovarian Krukenberg deposits in younger women with signet-ring rectal histology may present with a pelvic mass and abdominal swelling that is mistaken for a primary ovarian cancer until the bowel work-up is done. (See the NCI PDQ Rectal Cancer Treatment, metastatic disease section.)

Risk Factors for Rectal Cancer in Indian Patients Under 50

The ICMR National Centre for Disease Informatics and Research Hospital Based Cancer Registry data from a tertiary cancer centre Delhi and a tertiary cancer centre Hospital show a striking share of rectal cancer cases in Indian patients younger than 50, which is different from Western registries where the disease clusters above age 60. The strongest drivers in this Indian under-50 group are a positive family history of colorectal cancer, undiagnosed Lynch syndrome and other inherited cancer predisposition syndromes, long-standing inflammatory bowel disease in the form of ulcerative colitis or Crohn colitis, type 2 diabetes, central obesity, current smoking and a diet high in processed meat and refined carbohydrates and low in fibre, all consistent with the IARC Monograph 114 working group classification of processed meat as Group 1 carcinogenic to humans and red meat as Group 2A. Prior pelvic radiotherapy for childhood, testicular or gynaecological cancer is a smaller but real lifetime risk in long-term survivors. (See the IARC Monographs Volume 114 Red Meat and Processed Meat.)

Lynch Syndrome and FAP: Hereditary Drivers of Rectal Cancer

About five to seven per cent of rectal and colorectal cancers are linked to a clearly defined inherited cancer syndrome, and the a tertiary cancer centre Familial Cancer Clinic and a tertiary cancer centre Familial Cancer Clinic both run dedicated germline testing pathways for high-risk patients across the National Capital Region. Lynch syndrome (hereditary non-polyposis colorectal cancer) caused by germline mutations in MLH1, MSH2, MSH6, PMS2 or EPCAM is the most common, and is also associated with endometrial, ovarian, gastric, urothelial and small bowel cancers in the same family. Familial adenomatous polyposis (FAP) and the attenuated form, MUTYH-associated polyposis, Peutz-Jeghers syndrome, juvenile polyposis and PTEN hamartoma syndrome are rarer but important because they change colonoscopic surveillance intervals for unaffected family members. Universal MMR immunohistochemistry on every rectal biopsy at leading cancer centres in the region Memorial pathology is the screening step that flags these families for cancer genetics referral. (See the NCI PDQ Genetics of Colorectal Cancer.)

Diagnosing Rectal Cancer: Colonoscopy, Tattooing and Biopsy Protocol

Rectal cancer diagnosis begins with a full colonoscopy to the caecum with photo-documentation of the ileocaecal valve and biopsy of any suspicious lesion. Indian guidance from a tertiary cancer centre and a tertiary cancer centre recommends tattooing the rectal tumour or polyp site with sterile carbon ink to guide later laparoscopic or robotic TME, since the serosal surface gives few external clues once a small lesion has been removed endoscopically. Histology is reported per the College of American Pathologists protocol with grade, lymphovascular invasion, perineural invasion, tumour budding and margin status, and universal mismatch repair immunohistochemistry for MLH1, MSH2, MSH6 and PMS2 is now standard. If the colonoscope cannot pass an obstructing rectal lesion, CT colonography of the proximal colon is done within four weeks of resection to rule out a synchronous second primary, which is present in roughly three to five per cent of Indian colorectal cases reported from a tertiary cancer centre and a tertiary cancer centre series. (See the a tertiary cancer centre Evidence Based Management of Cancers in India, colorectal section.)

High-Resolution Pelvic MRI: The Mandatory Rectal Staging Scan

For rectal cancer the staging imaging is high-resolution pelvic MRI on a 3 Tesla magnet with thin-slice T2 sequences in axial, sagittal and coronal planes, supplemented by a contrast-enhanced CT of the chest, abdomen and pelvis to look for liver, lung and peritoneal disease. The MRI is read against the IRIA and Royal College of Radiologists structured template that records the T descriptor, the depth of extramural spread in millimetres, the mesorectal fascia status, extramural vascular invasion, the distance from the anal verge, sphincter complex involvement at the lower rectum, mesorectal nodal disease, and the lateral pelvic nodal compartment at the obturator and internal iliac stations. PET-CT is reserved for equivocal findings, suspected recurrence with rising CEA, or before resection of liver or lung metastases. a tertiary cancer centre, a tertiary cancer centre, ILBS, a leading cancer centre, a leading cancer centre Memorial, a leading cancer centre and a leading cancer centre Saket all report rectal MRI on this structured template at every staging MDT. (See the IRIA structured rectal MRI reporting template.)

Reflex Biomarkers in Rectal Cancer: Universal MMR, RAS and BRAF

Universal mismatch repair immunohistochemistry on every rectal biopsy and TME specimen is now standard practice at leading cancer centres in the region Memorial pathology, and loss of MLH1 and PMS2 staining triggers reflex BRAF V600E and MLH1 promoter methylation testing to separate sporadic from Lynch-pattern tumours, which are then sent for germline panel testing in the cancer genetics clinic. For metastatic rectal disease the minimum molecular set before first-line systemic therapy is KRAS exons two, three and four plus NRAS, BRAF V600E, HER2 amplification by IHC and FISH or NGS, and NTRK fusion testing, in line with ESMO 2023 and NCCN guidance adapted by the ICMR consensus document on colorectal cancer. Tests are run in-house at leading cancer centres in the region reference labs or sent to MedGenome, Strand, Core Diagnostics or accredited diagnostic laboratories for NCR private patients. CEA at baseline is the standard tumour marker tracked through treatment and follow up. (See the ICMR Consensus Document for Management of Colorectal Cancer.)

Stage 0 and Early Stage I Rectal Cancer: Local Excision via TEM and TAMIS

Stage 0 carcinoma in situ and favourable T1 sm1 rectal polyp cancers can be managed by complete endoscopic resection alone with three-monthly site checks for the first year and six-monthly thereafter. Favourable early rectal T1 lesions in the lower or middle rectum can be removed by transanal endoscopic microsurgery (TEM) or transanal minimally invasive surgery (TAMIS), routinely offered at a tertiary cancer centre GI surgery, a leading cancer centre colorectal unit and a leading cancer centre robotic surgery. The selection criteria are well or moderately differentiated histology, no lymphovascular or perineural invasion, no high tumour budding, sm1 invasion under 1000 microns, and a clear deep margin of at least 1 mm. Unfavourable T1 polyp cancers and sessile T1 sm2 or sm3 lesions need formal TME surgery with regional lymphadenectomy because the residual mesorectal nodal risk justifies the larger pelvic operation rather than transanal excision alone. Long-term outcomes after TEM and TAMIS for properly selected lesions are equivalent to TME in NCR series. (See the NCI PDQ Rectal Cancer Treatment, early stage section.)

Stage II and III Rectal Cancer: Total Neoadjuvant Therapy with RAPIDO and PRODIGE 23

The standard of care for most cT3, cT4 or node-positive mid and low rectal cancers across NCR has shifted decisively to total neoadjuvant therapy, where all the planned chemotherapy and radiation are given before TME surgery rather than split around the operation. Two regimens are in routine NCR use. The RAPIDO trial used short-course radiotherapy of 5 by 5 Gy followed by six cycles of CAPOX or nine cycles of FOLFOX before surgery and showed a halving of distant metastases at three years compared with standard chemoradiation, and is the preferred TNT backbone at a tertiary cancer centre and a tertiary cancer centre video MDT for fit patients with threatened MRF or EMVI positive disease. The PRODIGE 23 trial used induction FOLFIRINOX for six cycles followed by long-course chemoradiotherapy and surgery, with improved disease-free survival compared with chemoradiation alone, and is preferred at a tertiary cancer centre Rohini, a leading cancer centre and a leading cancer centre for younger fit patients with very advanced T4 rectal disease. (See the Bahadoer et al. RAPIDO trial in Lancet Oncology and the Conroy et al. PRODIGE 23 in Lancet Oncology.)

PROSPECT Trial: Selective Chemoradiation in Mid and Upper Rectal Cancer

Not every locally advanced rectal cancer needs the full long-course chemoradiation backbone. The PROSPECT trial published in the New England Journal of Medicine in 2023 by Schrag and colleagues randomised selected mid and upper rectal cancers without threatened mesorectal fascia and without bulky nodal disease to either FOLFOX alone with selective chemoradiation reserved for non-responders, or to the standard long-course chemoradiation backbone, and showed that FOLFOX alone is non-inferior in disease-free survival, local recurrence and overall survival. The trial gave an evidence base for de-escalating radiation in carefully chosen rectal patients, sparing the bowel, bladder, sexual and fertility morbidity that long-course pelvic radiation can cause. a tertiary cancer centre, a tertiary cancer centre video MDT, a tertiary cancer centre Rohini, leading cancer centres Memorial GI tumour boards have begun adopting the PROSPECT pathway cautiously for mid and upper rectal patients who meet the trial eligibility criteria, with continued long-course chemoradiation for low rectal disease and threatened MRF. (See the Schrag et al. PROSPECT in NEJM 2023.)

OPRA and Watch-and-Wait: Organ Preservation After TNT for Rectal Cancer

Watch-and-wait is the non-operative management strategy for patients with rectal cancer who achieve a clinical complete response after total neoadjuvant therapy. Instead of proceeding to TME surgery the patient is followed intensively with digital rectal examination, flexible sigmoidoscopy, rectal MRI and CEA every three months for the first two years, tapering thereafter, with salvage TME reserved for documented local regrowth. The OPRA trial by Garcia-Aguilar and colleagues randomised patients with locally advanced rectal cancer to two TNT sequencing strategies and showed that around half of the consolidation chemotherapy arm preserved their rectum at three years with no compromise in disease-free survival compared with patients who proceeded directly to TME. Candidates for watch-and-wait need a documented clinical complete response, willingness to commit to the intensive surveillance schedule and treatment at a specialised centre such as a tertiary cancer centre, a tertiary cancer centre video MDT, a tertiary cancer centre Rohini or a leading cancer centre with a dedicated rectal cancer clinic. (See the Garcia-Aguilar et al. OPRA trial in Journal of Clinical Oncology.)

dMMR Locally Advanced Rectal Cancer: Dostarlimab and AZUR-1

Mismatch repair deficient locally advanced rectal cancer is now treated with neoadjuvant single-agent immunotherapy at the leading Indian centres, on the basis of the Cercek dostarlimab study at Memorial Sloan Kettering and the larger AZUR-1 confirmatory cohort. Patients receive dostarlimab or pembrolizumab for six months and are then restaged with rectal MRI, flexible sigmoidoscopy and CEA, and the early data show that the great majority achieve a clinical complete response and avoid both pelvic radiation and TME surgery. a tertiary cancer centre, a tertiary cancer centre video MDT, a tertiary cancer centre Rohini, a leading cancer centre and selected NCR private GI tumour boards offer dostarlimab or pembrolizumab to dMMR rectal patients through compassionate access pathways or institutional protocols. The patient must commit to the same intensive surveillance schedule used for the watch-and-wait pathway after total neoadjuvant therapy, since salvage TME remains the back-up plan for any documented regrowth on follow-up imaging. (See the Cercek et al. PD-1 blockade in mismatch repair deficient locally advanced rectal cancer, NEJM.)

Stage IV Rectal Cancer First-Line: Sidedness, RAS Status and Biologic Choice

The first-line systemic strategy for Stage IV rectal cancer at leading cancer centres in the region Memorial, a leading cancer centre, a leading cancer centre Saket, a leading cancer centre Indraprastha, a leading cancer centre Dwarka, a leading cancer centre and a leading cancer centre Noida is decided by tumour sidedness and molecular profile. Rectal cancer arises in the left side of the colorectal continuum, and left-sided RAS and BRAF wild-type tumours show the strongest activity with a doublet of FOLFOX or FOLFIRI plus an anti-EGFR antibody (cetuximab or panitumumab), supported by the CALGB 80405, FIRE-3 and PARADIGM trials. RAS mutant rectal tumours receive a doublet plus bevacizumab. Resectable oligometastatic liver disease is taken to surgery with perioperative FOLFOX in line with the EORTC 40983 protocol. Potentially convertible liver-limited disease is treated with the most active triplet upfront, FOLFOXIRI plus bevacizumab, validated by the TRIBE and TRIBE2 trials, with reassessment for resection or thermal ablation every eight weeks. (See the Venook et al. CALGB 80405 in JAMA and the Yoshino et al. PARADIGM in JAMA.)

BRAF V600E, KRAS G12C and HER2 Amplified Rectal Cancer: Targeted Options

BRAF V600E mutant metastatic rectal cancer is biologically aggressive and is treated in the first line with FOLFOXIRI plus bevacizumab in fit patients, then encorafenib plus cetuximab in the second line on the basis of the BEACON CRC trial published in the New England Journal of Medicine. KRAS G12C mutant rectal disease has a dedicated second-line option of sotorasib plus panitumumab from CodeBreaK 300 and adagrasib plus cetuximab from KRYSTAL-10, available in NCR private centres on named-patient access. HER2 amplified RAS wild-type rectal disease responds to trastuzumab plus tucatinib (MOUNTAINEER trial) and to trastuzumab deruxtecan (DESTINY-CRC02). Mismatch repair deficient metastatic rectal disease is treated upfront with pembrolizumab monotherapy on the basis of KEYNOTE-177, which doubled progression-free survival versus chemotherapy, or with nivolumab plus low-dose ipilimumab from CheckMate 8HW and CheckMate 142. NTRK fusion positive rectal tumours qualify for larotrectinib or entrectinib. (See the Kopetz et al. BEACON CRC in NEJM and the André et al. KEYNOTE-177 in NEJM.)

Cost of Rectal Cancer Care Across Delhi, Gurgaon and Noida

Pricing for rectal cancer care across NCR varies with hospital tier, surgical approach and whether the patient uses generic or innovator brands of biologics. At a tertiary cancer centre Delhi, leading cancer centres, full diagnostic workup of colonoscopy with biopsy, CECT chest-abdomen-pelvis, rectal MRI 3T, CEA and universal MMR IHC is billed through general charges and typically costs INR 6,000 to 15,000 for non-paying category patients, and open or laparoscopic low anterior resection or abdominoperineal resection is billed at nominal rates of INR 10,000 to 40,000 inclusive of stay. At a tertiary cancer centre Rohini, package rates for laparoscopic LAR with TME run INR 2.2 to 3.8 lakh and APR with permanent colostomy INR 2.5 to 4.2 lakh. At a leading cancer centre, a leading cancer centre Saket, a leading cancer centre Memorial, a leading cancer centre Gurgaon, a leading cancer centre, a leading cancer centre Indraprastha, a leading cancer centre Dwarka, a leading cancer centre Noida and Felix Noida, laparoscopic TME packages range from INR 3.5 to 6.5 lakh and robotic TME from INR 5.5 to 10.5 lakh, with TEM or TAMIS for early rectal lesions at INR 1.2 to 2.8 lakh and CRS with HIPEC for peritoneal disease at INR 6.5 to 14 lakh. Long-course chemoradiation runs INR 15,000 to 45,000 at a tertiary cancer centre and INR 2.5 to 4.8 lakh at private centres. (See the National Health Authority PMJAY Health Benefit Package 2022 Oncology.)

Rectal Cancer FAQs for NCR Patients and Families

Will I need a permanent colostomy bag? Most rectal cancer patients today do not. With modern TME surgery, total neoadjuvant therapy and sphincter-sparing low anterior resection, the majority of rectal cancers above 5 cm from the anal verge can be treated without a permanent stoma, and a temporary loop ileostomy for eight to twelve weeks is common to protect the new join. Only very low rectal tumours involving the sphincter complex need an APR with a permanent colostomy, and even some of these patients qualify for organ preservation through watch-and-wait after a complete response to total neoadjuvant therapy under the OPRA protocol. What financial assistance exists? PMJAY Ayushman Bharat covers defined rectal surgery, radiation and chemotherapy packages at empanelled NCR hospitals, CGHS and DGEHS cover serving and retired government employees, Delhi Arogya Kosh and Delhi Arogya Nidhi cover Delhi-domicile patients, and the Health Minister’s Cancer Patient Fund and Rashtriya Arogya Nidhi provide assistance up to INR 15 lakh for BPL patients at a tertiary cancer centre and other regional cancer centres. CanSupport, Indian Cancer Society, CanKids and Ugam offer travel and counselling support. (See the Health Minister’s Cancer Patient Fund and Rashtriya Arogya Nidhi guidelines.)